News about Biotechnology

GENESIS Pharma Secures Exclusive Rights to Commercialise Donidalorsen Across 14 CEE Markets

GENESIS Pharma, a regional biopharma company specialising in the commercialisation of innovative medicines in Central and Eastern Europe (CEE), has entered into an exclusive agreement with Otsuka Pharmaceutical Europe Ltd., the European arm of Otsuka Pharmaceutical Co., Ltd., for the distribution and commercialisation of donidalorsen.

Biotechnology | 16/12/2025 | By Darshana

Vektor Medical Secures FDA Clearance for Next-Generation vMap Arrhythmia Mapping Technology

Vektor Medical, a San Diego–headquartered medical technology company focused on advancing arrhythmia diagnosis and treatment, has received US Food and Drug Administration 510(k) clearance for its next-generation vMap technology.

Biotechnology | 14/12/2025 | By Darshana |  109

Sentynl Appoints myTomorrows as Global Provider to Expand Managed Access Program

Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP).

Biotechnology | 11/12/2025 | By Darshana

Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada

Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.

Biotechnology | 10/12/2025 | By Darshana

Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa

Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.

Biotechnology | 09/12/2025 | By Darshana

Rondo Therapeutics Begins First-in-Human Trial of Novel CD28 - Nectin-4 Bispecific for Solid Tumours

Rondo Therapeutics, a clinical-stage biopharmaceutical company developing next-generation T-cell engaging bispecific antibodies for solid tumours, has begun dosing patients in its phase 1/1b clinical trial of RNDO-564.

Biotechnology | 07/12/2025 | By Darshana

Cytiva and Veeda Lifesciences Launch New HCP Services Centre

The collaboration between Cytiva and Veeda Lifesciences brings a dedicated Host Cell Protein (HCP) services centre offering comprehensive HCP coverage, characterization, and quantification assays, enabling global biopharma companies to enhance the safety, efficacy, and quality of their biologics development

Biotechnology | 28/11/2025 | By Dineshwori |  109

Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.

Biotechnology | 27/11/2025 | By Darshana

Biogen Partners with Dayra Therapeutics to Develop Oral Macrocyclic Peptide Treatments for Immunological Diseases

Biogen Inc. has entered into a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides targeting high-priority immunological conditions.

Biotechnology | 26/11/2025 | By Darshana

Harbour BioMed Advances Global Biotherapeutics Collaboration With AstraZeneca

The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.

Biotechnology | 25/11/2025 | By Darshana